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PML is induced by oncogenic ras
and promotes premature senescence
Gerardo Ferbeyre,1 Elisa de Stanchina,1 Emmanuelle Querido,1 Nicole Baptiste,2 Carol Prives,2
and Scott W. Lowe1,3
1Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724 USA; 2Department of Biological Sciences,
Columbia University, New York, New York 10027 USA
Oncogenic ras provokes a senescent-like arrest in human diploid fibroblasts involving the Rb and p53 tumor
suppressor pathways. To further characterize this response, we compared gene expression patterns between
ras-arrested and quiescent IMR90 fibroblasts. One of the genes up-regulated during ras-induced arrest was
promyelocytic leukemia (PML) protein, a potential tumor suppressor that encodes a component of nuclear
structures known as promyelocytic oncogenic domains (PODs). PML levels increased during both ras-induced
arrest and replicative senescence, leading to a dramatic increase in the size and number of PODs. Forced PML
expression was sufficient to promote premature senescence. Like oncogenic ras, PML increased the levels of
p16, hypophosphorylated Rb, phosphoserine-15 p53, and expression of p53 transcriptional targets. The fraction
of Rb and p53 that colocalized with PML markedly increased during ras-induced arrest, and expression of PML
alone forced p53 to the PODs. E1A abolished PML-induced arrest and prevented PML induction and p53
phosphorylation in response to oncogenic ras. These results imply that PML acts with Rb and p53 to promote
ras-induced senescence and provide new insights into PML regulation and activity.
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Normal cells possess natural defenses that minimize the
deleterious consequences of mutations, and these safe-
guards are often disrupted during multistep carcinogen-
esis. One such safeguard involves antiproliferative re-
sponses to excessive mitogenic signaling or oncogenic
stress. For example, forced expression of the c-myc on-
cogene drives proliferation and simultaneously increases
cellular susceptibility to apoptosis (Evan et al. 1992). Al-
though the decision to proliferate or die can be influ-
enced by additional factors, mutations that disable apop-
tosis allow uncontrolled proliferation and cooperate
with myc during tumor development (Sherr and Weber
2000). Similarly, oncogenic ras promotes uncontrolled
mitogenesis but when expressed in primary cells, pro-
vokes a permanent cell cycle arrest with features of se-
nescence (Serrano et al. 1997). As a result, ras-induced
arrest suppresses oncogenic transformation (Serrano et
al. 1997; Lin et al. 1998; Hahn et al. 1999). Indeed, the
necessity to override this arrest explains the cooperative
interactions between ras and immortalizing mutations
for transformation and may be important during tumor
progression (Serrano et al. 1997; Hahn et al. 1999).
Senescence was originally defined by the observation
that primary cells have a genetically determined limit to
their proliferative capacity; after which they perma-
nently arrest with characteristic features (Hayflick 1965;
for review, see Campisi 1997). Owing to the “end-repli-
cation problem”, telomeres shorten during each cell di-
vision unless telomerase is expressed, and it appears that
some aspect of telomere malfunction induces the senes-
cent cell-cycle arrest (reviewed by Artandi and DePinho
2000). Although oncogenic ras does not promote telo-
mere shortening (Shelton et al. submitted), the charac-
teristics of ras-arrested cells are similar to cells under-
going replicative senescence. For example, cells arrested
by serial passaging or oncogenic ras accumulate a senes-
cence-associated -galactosidase (SA--gal) (Dimri et al.
1995; Serrano et al. 1997). Moreover, these cells display
similar patterns of gene expression that are markedly
distinct from quiescent cells (Shelton et al. 1999). DNA
damaging agents and other mitogenic oncogenes can also
induce a senescent-like phenotype (Linke et al. 1997; Lin
et al. 1998; Zhu et al. 1998; Chang et al. 1999; Dimri et
al. 2000), implying that the process of cellular senes-
cence reflects a common arrest program that is activated
by diverse stimuli.
The most compelling link between ras-induced senes-
cence and tumor suppression is their mutual dependence
on tumor suppressor genes. For example, oncogenic ras
induces p53, p15INK4b, p16INK4a, and p19ARF and leads to
hypophosphorylation of Rb in several normal rodent and
human cell types (Serrano et al. 1997; Palmero et al.
1998; Malumbres et al. 2000). Inactivation of either p53,
p19ARF, or the INK4a/ARF locus bypasses ras-induced
arrest in murine fibroblasts (Kamijo et al. 1997; Serrano
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et al. 1997; Palmero et al. 1998), and overexpression of
these proteins is sufficient to induce senescence in some
settings (Sugrue et al. 1997; Uhrbom et al. 1997; Mc-
Connell et al. 1998; Stott et al. 1998; Vogt et al. 1998;
Wang et al. 1998a; Dimri et al. 2000). Viral oncoproteins
that target the p53 and Rb pathways circumvent ras-
induced arrest and cooperate with ras in oncogenic trans-
formation (Serrano et al. 1997; Hahn et al. 1999; Morales
et al. 1999). However, since the p53 and Rb pathways can
also promote reversible checkpoint arrests, it is not ob-
vious how senescence is maintained.
The mechanistic differences in the control of cellular
senescence between human and murine cells have im-
portant ramifications for multistep carcinogenesis in
each species. For example, species-specific differences in
the control of replicative senescence involve variations
in telomere length and dynamics, and this accounts for
the unique requirement for telomerase activation during
the transformation of human cells (Hahn et al. 1999). In
contrast, species-specific differences in the control of
premature senescence are unrelated to telomere biology
but involve the relative contribution of the p53 pathway
to the process (Serrano et al. 1997). Although oncogenic
ras activates the p53 and Rb pathways in cells from both
species, disruption of the p53 pathway is sufficient to
override ras-induced arrest only in murine cells (Serrano
et al. 1997; Palmero et al. 1998). As a consequence, mu-
rine cells lacking p53 are transformed by oncogenic ras,
whereas inactivation of p53 in human cells does not res-
cue ras-induced arrest (Serrano et al. 1997). The only
known activities that circumvent ras-induced arrest in
human cells are viral oncoproteins such as adenovirus
E1A, SV40 T antigen, papillomavirus E6/E7, and herpes
virus LMP1 (Serrano et al. 1997; Hahn et al. 1999; Mo-
rales et al. 1999; Yang et al. 2000). These proteins typi-
cally disable both the p16/Rb and p53 growth arrest but
may also have additional targets. Therefore, escape from
ras-induced arrest in human cells requires the evasion of
multiple tumor suppressor pathways, the nature of
which remains to be fully elucidated.
In this study, we set out to gain insights into the con-
trol of ras-induced senescence in human cells. We hy-
pothesized that the onset of senescence involves a gene
expression program that, in response to an initiating
stimulus, gives rise to the senescent phenotype. To in-
vestigate this program, we conducted a differential gene
expression screen to identify genes that were specifically
altered during ras-induced senescence but not in quies-
cent-like arrests. Using this approach, we identify PML
as a component of the premature senescence program
induced by oncogenic ras, and provide evidence that
PML acts in senescence control, in part, by modulating
the p53 and Rb tumor suppressor pathways.
Results
PML is induced during premature senescence
We screened a cDNA array to identify transcripts that
were differentially expressed between ras-arrested and
quiescent cells. Oncogenic ras was introduced into
whole populations of IMR90 human diploid fibroblasts
using retroviral-mediated gene transfer. Cells were re-
covered ten days post-infection, at which time they had
arrested at subconfluent density and were highly posi-
tive for SA--gal activity (>95% positive). For compari-
son, a parallel culture of IMR90 cells was infected with a
control “empty” vector, and the cells were grown to con-
fluence where they arrested by contact. These cells were
quiescent and not positive for SA--gal (<10%). Impor-
tantly, both ras-expressing and quiescent cell popula-
tions displayed a similar reduction in 3H-thymidine in-
corporation relative to exponentially growing controls
(data not shown). 33P-labeled cDNA probes derived from
mRNA from ras-arrested and quiescent cells were used
to hybridize to Genome Systems cDNA arrays contain-
ing <18,000 known genes and expressed sequence tags
(ESTs). Approximately 150 genes displayed greater than
fivefold changes in two separate experiments. A series of
genes known to be altered during replicative senescence
and ras-induced arrest were also identified on the arrays
(see Materials and Methods), although many of the dif-
ferentially expressed genes were ESTs of unknown func-
tion.
Several known genes not previously associated with
cellular senescence were differentially expressed in ras-
arrested cells. One of the most interesting up-regulated
genes was PML (7.5-fold increase) (Fig. 1A). PML is a
RING finger protein that localizes to large nuclear struc-
tures called promyelocytic oncogenic domains (PODs),
ND10, or PML nuclear bodies (for review, see Zhong et
al. 2000). PML was initially identified in acute promy-
elocytic leukemia (APL), in which it forms a reciprocal
translocation t(15;17) with the RAR gene (de The et al.
1991; Goddard et al. 1991; Kakizuka et al. 1991; Kastner
et al. 1992). In APL cells, the PML–RAR fusion protein
disrupts the PODs, but addition of retinoic acid disables
the fusion protein leading to reformation of the PODs
and differentiation (Dyck et al. 1994; Weis et al. 1994).
These studies imply that PML has tumor-suppressor ac-
tivity, which is supported by the observation that mice
lacking PML are tumor prone (Wang et al. 1998b). Al-
though the biochemical action of PML is not known, it
may function in transcription control by recruiting tran-
scription factors to the PODs (LaMorte et al. 1998; Dou-
cas et al. 1999).
To further characterize the effects of oncogenic ras on
PML, Northern blots were performed using probes
against PML or a series of other senescence-related genes
identified on our arrays. ras-arrested cells displayed a
dramatic induction in several PML isoforms, and in the
senescence-related markers PAI-1, stromelysin, and IL-
1 (Fig. 1B). IMR90 cells that underwent replicative se-
nescence by serial passaging also induced PML. Consis-
tent with a previous report (Shelton et al., unpubl.), the
levels of stromelysin and IL-1 induced by oncogenic ras
were more pronounced than during replicative senes-
cence (Fig. 1B), perhaps because Ras signaling directly
activates these genes (Sistonen et al. 1989), or because
the onset of senescence is more synchronous in ras-ex-
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pressing cells. In any case, E1A, which overrides ras-
induced arrest, abolished the upregulation of PML and
the other senescence-associated markers in response to
oncogenic ras.
PML oncogenic domains accumulate in response
to oncogenic ras
PML is the defining component of nuclear structures
known as promyelocytic oncogenic domains (PODs).
These structures also contain Sp100, a target of autoan-
tibodies in primary billiary cirrhosis and also up-regu-
lated in our arrays from ras-arrested cells (data not
shown). To examine the impact of oncogenic ras on POD
numbers and distribution, we examined the expression
of PML and Sp100 by indirect immunofluorescence us-
ing specific antibodies. Oncogenic Ras induced the accu-
mulation of nuclear bodies containing both PML and
Sp100 and a similar increase was observed in senescent
cells (Fig. 2A). To quantify this effect we conducted se-
rial confocal microscopy on 100 randomly-chosen nuclei
from control and ras-arrested cells (Fig. 2B). Cells ar-
rested by oncogenic ras were positive for SA--gal and
displayed a striking increase in the number, size, and
intensity of the PODs relative to controls (37 ± 13 vs.
12 ± 6, respectively; see Fig. 2B). In contrast, cells ar-
rested by serum-depletion, confluence, or forced p53 ex-
pression displayed low SA--gal activity and did not ac-
cumulate PODs (Fig. 2C). Consistent with the Northern
analysis presented in Figure 1B, this increase in PODs in
response to ras was not observed in cells expressing E1A
(Fig. 2D).
Expression of oncogenic ras in IMR90 cells produces
an initial mitogenic burst followed by the onset of cel-
lular senescence (Lin et al. 1998). During this mitogenic
period (e.g., 2 days postselection), ras-expressing cells
were not positive for SA--gal and contained few PODs
(Fig. 2E). However, PML bodies increased dramatically
by day 4 and achieved a maximum at day 6 postinfection,
co-incident with the time in which the cells underwent
cell-cycle arrest and accumulated SA--gal (Fig. 2E).
Thus, the accumulation of PODs in response to onco-
genic ras is coincident with the onset of premature se-
nescence and appears unique to the senescent state.
PML induces premature senescence
PML can inhibit cellular proliferation in a variety of tu-
mor cell lines (for review, see Melnick and Licht 1999),
but the consequences of stable PML expression in nor-
mal cells are poorly characterized. Therefore, we intro-
duced PML into IMR90 and IMR90 (E1A) populations by
retroviral-mediated gene transfer and measured BrdU in-
corporation to estimate DNA synthesis (Fig. 3B,C). By 10
days postinfection, forced PML expression in IMR90
cells produced a marked increase in POD numbers and
intensity (40 ± 10; Fig. 3A), as well as a fivefold reduction
in the percentage of BrdU-positive cells, suggesting a po-
tent growth arrest (Fig. 3B). E1A-expressing cells dis-
played a similar increase in POD numbers (40 ± 5) and
PML levels (data not shown), although the intensity of
PML staining in PODs was reduced (Fig. 3A). Moreover,
in ∼25% of E1A-expressing cells, a substantial portion of
the PML was localized to cytoplasmic conglomerates
(Fig. 3A, arrow). The percentage of BrdU-positive cells
coexpressing PML and E1A was similar to that observed
in cells expressing E1A alone (Fig. 3B,C), implying that
E1A completely abolished PML-induced arrest. Neither a
PML mutant lacking the nuclear localization signal
(PMLnls-) or the proline rich RING finger B-box-1 (PML-
prb-) were able to promote cell cycle arrest in a 3H-thy-
midine incorporation assay (Fig. 3D). Although these
PML mutants were efficiently expressed, they were un-
able to induce formation of PODs (data not shown).
To further characterize PML-induced arrest, we used a
growth assay that measures cell accumulation with time
and examined the cell-cycle distribution of arrested cells
following BrdU incorporation and flow cytometry. As
expected, cells expressing oncogenic ras arrested after an
initial period of growth (Fig. 4A, circles). In contrast,
PML-expressing cells grew slowly from the beginning
Figure 1. Oncogenic ras induces PML. (A) 33P-labeled cDNA
probes were generated from quiescent (top) and ras-arrested
(bottom) IMR90 fibroblasts and used to hybridize to GDA ar-
rays. The portion of each array that contains the PML cDNA
(n-5, see arrows) is shown; each cDNA is arrayed in duplicate
and in different orientations (see www.genomesystems.com).
Note that the cDNAs located at p-1 and 1–1 are controls that
show equal intensity between the filters, whereas several other
cDNAs in this section displayed up- or down-regulation in ras-
arrested cells. (B) Northern blot analysis of PML and the senes-
cence-related genes PAI-1, stromelysin, and IL-1. IMR90 cells
were infected with a control vector (V), oncogenic ras (R), or
coinfected with E1A and oncogenic ras (ER). Alternatively, the
cells were serially passaged until they had become senescent (S).
Three major transcripts were visualized for PML (Goddard et al.
1991). The smaller of the two PAI-1 transcripts is the one whose
up-regulation correlates better with senescence (Mu and Hig-
gins 1995).
PML and premature senescence
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Figure 2. PODs accumulate during premature senescence. PML and Sp100 localization in IMR90 cells was determined by indirect
immunofluorescence using the PGM3 monoclonal antibody and the rabbit Anti-Sp100 polyclonal antibody AB1380. To facilitate
comparison, photomicrographs of each cell were prepared using identical microscope settings and exposure times. In all instances,
similar results were obtained with a polyclonal antibody directed to a different epitope of human PML (see Materials and Methods).
(A) Confocal images of costaining for PML and Sp100 in cells expressing an empty vector (V), oncogenic ras (R) and senescent cells (S).
(B) PML staining in a representative series of cells expressing an empty vector (V) and oncogenic ras (R). (C) PML staining in
exponentially growing subconfluent (SC) cells was compared to cells arrested by confluence (C), low serum (LS), or enforced p53
expression. (D) PML staining in cells expressing E1A or coexpressing E1A and oncogenic ras. (E) PML staining of ras-expressing cells
fixed 2, 4, 6, and 10 days after selection for cells expressing oncogenic ras. In panels B–D, the percentage of SA--gal positive cells in
each population is indicated below each picture.
Ferbeyre et al.
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and never reached the densities observed in ras-express-
ing cells (Fig. 4A, squares). However, upon achieving ar-
rest, cells expressing either oncogenic ras or PML dis-
played similar cell-cycle profiles, with a prominent G1/
G2 arrest and loss of S phase DNA content (Fig. 4B). PML
induced the accumulation of SA--gal and the senes-
cence-related form of PAI-1, although the intensity of
each marker was not as intense as that produced by on-
cogenic ras (Fig. 5). Thus, PML is sufficient to promote
cell-cycle arrest and premature senescence. These re-
sults show that the biological properties of ras- and PML-
arrested cells are highly similar and are consistent with
a causal role for PML in ras-induced senescence.
PML activates the Rb and the p53 tumor
suppressor pathways
Previous studies demonstrate that the Rb and p53 path-
ways contribute to premature senescence induced by on-
cogenic ras (Serrano et al. 1997; Lin et al. 1998; Zhu et al.
1998; Morales et al. 1999). Rb is an active growth inhibi-
tor in its hypophosphorylated form, leading to repression
of E2F-responsive genes (Dyson 1998). Like cells arrested
by oncogenic ras, cells arrested by PML expressed only
hypophosphorylated Rb and no cyclin A, an E2F-depen-
dent gene (Fig. 6A) (Vigo et al. 1999). Although these
changes can be passively associated with cell-cycle ar-
rest, both oncogenic ras and PML also induced p16INK4a,
a cyclin-dependent kinase inhibitor that actively pre-
vents Rb phosphorylation and is not induced during
most cell-cycle arrests (Serrano 1997). Hence, PML ap-
pears to actively engage the Rb tumor suppressor path-
way.
p53 is activated by a variety of signals, some of which
produce specific p53 posttranslational modifications (Gi-
accia and Kastan 1998; Prives 1998). For example, p53
phosphorylation on serine 15 accumulates following
DNA damage and during replicative senescence (Shieh et
al. 1997; Siliciano et al. 1997; Webley et al. 2000) and
may activate p53 by compromising the Mdm2–p53 in-
teraction and increasing the affinity of p53 for the CBP
transcriptional coactivator (Lambert et al. 1998; Dumaz
and Meek 1999). Consistent with previous reports (Ser-
rano et al. 1997; Lin et al. 1998), oncogenic ras induced
p53 protein, which corresponded to an increase in the
p53 transcriptional targets p21 and Mdm2 (Fig. 6A–C, cf.
Figure 3. Impact of enforced PML expression on IMR90 cells. (A) IMR90 cells or IMR90 cells expressing E1A were infected with a
control vector (V) or a virus expressing PML. PML staining and POD structure were visualized by indirect immunofluorescence using
46-diamidino-2-phenylindole (DAPI) staining to highlight the nucleus. Representative samples are shown. The arrow in the bottom
right panel (E1A) points to a cytoplasmic PML conglomerate. (B) Cell morphology and in situ bromodeoxyuridine (BrdU) incorporation
of control IMR90 cells or E1A-expressing IMR90 (E1A) cells infected with an empty vector (V), or viruses expressing oncogenic ras (R)
or PML (P). The cells were pulsed with 10 µM BrdU for 2 hours a day 4 postselection, and BrdU incorporation was visualized using
immunohistochemistry. (C) Quantitation of the results presented in B, showing the percentage of BrdU-positive nuclei. The average
and standard deviation of three independent counts of 200 cells are shown. The abbreviations are as follows: (V) vector; (R) oncogenic
ras; (P) PML; (E) E1A. (D) 3H-thymidine incorporation in cells containing a vector control (V), PML, oncogenic ras, or two PML mutants,
PML Nls- and PML prb-. All cell populations were pulsed with 3H-thymidine for 24 hours, beginning 3 days postselection and the
amount of incorporation was measured as described in Materials and Methods. Each point represents the mean ± standard deviation
of data obtained in three independent experiments.
PML and premature senescence
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lanes V and R). Forced PML expression produced a simi-
lar effect, albeit to a lesser degree (Fig. 6A–C, lane P). To
determine whether oncogenic ras or PML promote p53
phosphorylation on serine 15, immunoblotting was per-
formed using antibodies that specifically recognize phos-
phoserine-15 p53 (PS-15 p53). PS-15 p53 was barely de-
tectable in control cells but was dramatically induced by
oncogenic ras (Fig. 6C, cf. lanes V and R). In contrast,
induction of p53 protein by retroviral transduction of
p53 produced no increase in PS-15 p53 (Fig. 6C, lane p53).
Although PML induced only a modest accumulation of
p53 protein, this was accompanied by a substantially
greater increase in PS-15 p53 (Fig. 6C, cf. lanes V and P).
Of note, the effect of PML on PS-15 was more apparent in
cells expressing ectopic p53 (Fig. 6C, p53 +P). Consistent
with our previous results (de Stanchina et al. 1998), PS-
15 p53 was not detected in IMR90 cells expressing E1A
(Fig. 6D, lane E). In fact, E1A suppressed the accumula-
tion of PS-15 p53 in response to oncogenic ras (Fig. 6D,
lanes R and ER). This suppression may involve the E1A-
p300/CBP interaction, for cells expressing E1A mutants
unable to bind p300/CBP induced PS-15 p53 (data not
shown). Therefore, like oncogenic ras, PML can activate
the p53 tumor suppressor pathway in a manner that is
modulated by E1A.
Oncogenic ras and PML promote Rb and p53
relocalization to the PODs
PML can modulate transcription by recruiting transcrip-
tion factors to the PODs, and both Rb and p53 can lo-
calize to PODs under certain circumstances (Alcalay et
al. 1998; Lain et al. 1999). To determine whether endog-
enous PML colocalizes with Rb during premature
senescence, we conducted confocal laser scanning
immunofluorescence microscopy on control (vector
only) and ras-arrested cells using a PML monoclonal an-
tibody and a polyclonal antibody that recognizes the
carboxyl terminus of Rb. In both vector-control and
ras-arrested cells, Rb was predominantly observed in
small nuclear speckles that displayed no obvious over-
lap with the PODs (Fig. 7A). However, a portion of Rb
in ras-arrested cells formed larger nuclear bodies that
colocalized with the PODs or were immediately adja-
cent to them. Although only a relatively small percent-
age of PODs contained Rb in ras-arrested cells, it was
highly reproducible and represented a tenfold increase
relative to that observed in controls (14% vs. 1%, respec-
tively).
To determine whether PML colocalized with p53 dur-
ing ras-induced arrest, a similar series of experiments
were performed using antibodies against PML and p53.
Although p53 did not colocalize with PML in control
cells, a striking colocalization of p53 and PML was ob-
served in ras-arrested cells (Fig. 7B). Only a subset of the
endogenous p53 associated with the PODs, but each
POD contained p53. To confirm and extend this result,
IMR90 cells were coinfected with retroviruses express-
ing a p53-GFP fusion protein and retroviruses expressing
either oncogenic ras or PML. Upon the induction of pre-
mature senescence, the localization of p53 and PML
were determined by confocal fluorescence microscopy
using GFP or antibodies against PML. As expected, p53-
GFP was expressed in the nucleus of control (vector only)
cells and oncogenic ras promoted colocalization of a sub-
set of GFP with PML (Fig. 7C). Virtually all of the p53-
GFP colocalized with the PODs in PML-arrested cells,
implying that PML can force p53 re-localization to the
PODs. The fact that both oncogenic ras and PML can
promote relocalization of p53 to the PODs is consistent
with a role for PML in ras-induced arrest and may ex-
plain how PML activates p53.
Figure 4. Characteristics of PML-induced arrest. (A) Growth curves of IMR90 cells containing empty vector (), oncogenic ras () or
PML (). Each value was determined in triplicate and normalized to the cell number at day 0, which corresponded to the time in which
the cells finished drug selection. (B) Cell-cycle analysis of populations containing an empty vector, oncogenic ras or PML. The cells
were pulsed with BrdU for 4 hours and analyzed for BrdU uptake and DNA content by two-color flow cytometry using a fluorescein
isothiocyanate (FITC)-conjugated anti-BrdU antibody and propidium iodide (see Materials and Methods). The percentage of BrdU
incorporation is indicated at the top of each panel.
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Discussion
PML contributes to premature senescence
Expression of oncogenic ras in human diploid fibroblasts
triggers a premature senescence program that limits the
promitogenic consequences of excessive Ras signaling.
Using a differential gene expression screen, we identified
the candidate tumor suppressor PML as a gene up-regu-
lated during ras-induced senescence. Several observa-
tions suggest that PML actively contributes to this pro-
gram. First, the onset of cellular senescence is accompa-
nied by a striking increase in size and number of the
PODs. This increase is relatively specific for cells under-
going senescence, because PODs accumulate during rep-
licative senescence (see also, Jiang and Ringertz 1997)
but not during the nonsenescent arrests induced by
growth factor withdrawal, contact inhibition, or p53
overexpression. Second, like oncogenic ras, forced ex-
pression of PML is sufficient to induce premature senes-
cence. Hence, PML induction is not simply associated
with the senescent state. Third, as in ras-induced arrest,
PML-induced arrest is accompanied by engagement of
the Rb and p53 tumor suppressor pathways. Both onco-
genic ras and PML induce p16, Rb hypophosphorylation,
PS-15 p53, and p53 transcriptional targets. Fourth, onco-
genic ras promotes the relocalization of a subset of Rb
and p53 to the PODs. Finally, E1A, which overrides ras-
induced arrest and disables the Rb and p53 arrest pro-
grams, prevents PML induction by oncogenic ras and
abolishes PML-induced arrest. Thus, PML can promote
premature senescence and may modify the tumor-sup-
pressor effects of the Rb and p53 pathways.
Regulation of PML
Oncogenic ras induces premature senescence, in part, by
constitutively signaling through the MAP Kinase
Figure 6. PML engages the Rb and p53 pathways. (A) The ex-
pression of Rb, cyclin A, p16, and p53 was measured by immu-
noblotting of lysates from IMR90 cells containing an empty
vector (V), oncogenic ras (R) or PML (P). (B) Expression of p53
targets p21 and mdm2 by Northern blot analysis of total RNA
extracted from the cells indicated above. (C) p53 phosphoryla-
tion on serine 15 was detected by immunoblotting using anti-
bodies that specifically bind PS-15 p53. Lysates were prepared
from cells infected with a empty vector (V), oncogenic ras (R),
wild-type human p53 (p53), PML (P), or both the p53 and PML
expressing viruses (p53 +P). The expression of total p53 was
measured using a polyclonal antibody that recognizes all p53.
The expression of the p53-target p21 is shown for comparison.
Lysates were prepared from cells containing an empty vector
(V), oncogenic ras (R), p53, PML (P) and a combination of p53
and PML (p53 +P). (D) The impact of E1A on PS-15 p53 was
determined as in B, in which (ER) indicates cells co-expressing
E1A and oncogenic ras.
Figure 5. PML induces premature senescence. (A) IMR90 cell
populations containing an empty vector (V), oncogenic ras (R) or
PML were stained for SA--gal 6 days postselection. IMR90 cells
that were serially passaged until senescent (S) are shown for
comparison. Representative photomicrographs are shown; se-
nescent-cells display a cytoplasmic blue stain. (B) Quantitation
of data in A, showing the percentage of SA--gal positive cells.
The data represent the mean ± standard deviation of three in-
dependent counts of 200 cells. (C) Expression of PAI-1 in the
indicated populations was measured by Northern blot.
PML and premature senescence
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(MAPK) cascade (Lin et al. 1998; Zhu et al. 1998). MAPK
signaling also contributes to PML induction, because the
size and intensity of the PODs increased after expression
of oncogenic raf (data not shown). However, PML bodies
are not induced immediately in response to oncogenic
ras but appear after an initial mitogenic burst coincident
with senescence. These data suggest that Ras signaling
to PML is indirect and, like the senescence process itself,
reflects a cellular response to some aspect of inappropri-
ate mitogenic signaling. Of note, interferon also induces
PML and other components of the PODs (Guldner et al.
1992; Korioth et al. 1995; Lavau et al. 1995; Stadler et al.
1995). Several additional interferon-responsive genes
were induced by oncogenic ras on our cDNA arrays,
including Sp100, which encodes another POD compo-
nent (see Fig. 2A)(Guldner et al. 1992). These data
raise the possibility that components of the interferon
signal transduction program contribute to ras-induced
arrest. Consistent with this view, E1A interferes with
both ras-induced arrest and interferon signaling (Gutch
and Reich 1991; Bhattacharya et al. 1996; Serrano et al
1997), and disruption of the interferon response factor-1
cooperates with oncogenic ras during transformation
and tumorigenesis (Tanaka et al. 1994; Nozawa et al.
1999).
PML action in premature senescence
How PML acts in tumor suppression is not firmly estab-
lished. Previous studies using human tumor cells or
knockout mice suggest that PML can influence cell-
cycle control, differentiation, and apoptosis (Dyck et al.
1994; Weis et al. 1994; Wang et al. 1998a,b). None of
these PML activities are well understood at the mecha-
nistic level, but it is often assumed that PML acts by
recruiting other proteins to the PODs (Zhong et al. 2000).
The ability of PML to form PODs appears essential for its
prosenescence activity, because two PML mutants un-
able to form PODs are unable to induce premature se-
nescence. Our results indicate that PML contributes to
the control of cellular senescence, in part, by modulating
the Rb and p53 tumor suppressor pathways (Fig. 8). This,
too, may involve the ability of PML to recruit Rb and p53
to the PODs, because the fraction of p53 and Rb that
colocalizes with PODs dramatically increases in re-
sponse to oncogenic ras. In principle, these structures
might recruit Rb and p53 to sites of transcriptional re-
pression or activation, respectively, or they might act as
transient docking sites to assemble the active transcrip-
tion complexes that then migrate to other areas in the
nucleus.
Although our data show that PML can engage the Rb
and p53 pathways, they do not show an absolute require-
ment for either pathway in the arrest; nor do they rule
out the possibility that PML has additional effects (Fig.
8). Hence, inactivation of either pathway alone is unable
to override premature senescence (data not shown; Ser-
rano et al. 1997). Furthermore, it is possible that PML
itself is not required for premature senescence, because
all attempts to disable PML function using antisense in-
hibition or putative dominant-negative proteins were
unable to override ras-induced arrest (data not shown).
Figure 7. Colocalization of PML, Rb, and p53 by laser scanning
confocal microscopy. (A) Representative images of IMR90 cells
containing an empty vector (V) or oncogenic ras (R) costained
with anti-pRb and anti-PML antibodies. (B) Representative im-
ages of IMR90 cells containing an empty vector (V) or oncogenic
ras (R) costained with anti-p53 and anti-PML antibodies. (C)
Representative images of cells expressing a p53-green fluorescent protein (GFP) fusion protein and either a control vector (V),
oncogenic ras (R), or PML (P). In this series, p53 was localized by direct GFP fluorescence, whereas PML was localized using an
anti-PML antibody.
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We suspect that in human cells inactivation of both the
Rb and p53 pathways is required to circumvent PML-
induced arrest. E1A abolishes the Rb pathway by binding
Rb (Whyte et al. 1988) and interferes with the p53 cell-
cycle arrest checkpoint (Lowe et al. 1993), perhaps
through the E1A-p300/CBP interaction (Lill et al. 1997).
Thus, E1A interferes with both the p53 and Rb growth
arrest pathways and abrogates ras- and PML-induced ar-
rest (Fig. 3; see also Serrano et al. 1997). Nevertheless,
E1A may also interfere with an Rb- and p53-independent
activity of PML.
Together, our data indicate that the control of prema-
ture senescence in human cells involves a tumor-sup-
pressor network rather than a single antiproliferative
pathway (Fig. 8). This tight control of ras-induced senes-
cence in human cells is in contrast to the more relaxed
control observed in murine cells, in which induction of
ras-induced arrest depends strictly on the ARF-p53 path-
way (Serrano et al. 1997; Palmero et al. 1998). Interest-
ingly, in MEFs, oncogenic ras induces PML in a p53-
dependent manner, and p53 is required for PML-induced
arrest (E. Querido and S.W.Lowe, unpubl.). This observa-
tion is reminiscent of the ability of E1A to prevent both
PML accumulation and PML-induced arrest and suggests
that PML may operate in a positive-feedback loop that
ultimately leads to a permanent cell-cycle arrest. We
suspect that the more stringent control of premature se-
nescence in human cells relates to the more prominent
role of the Rb pathway. Accordingly, disruption of p53
alone immortalizes rodent cells, whereas the ability of
certain viral oncoproteins to evade replicative senes-
cence in human cells depends, in part, on their ability to
bind Rb (Morales et al. 1999).
Implications for p53 regulation and activity
Oncogenic ras induces p53 levels and activity, in part,
through the MAPK cascade (Lin et al. 1998). The data
presented here imply that PML contributes to p53 acti-
vation, perhaps by recruiting p53 to the PODs (see
above). Importantly, PML is unable to increase p53 levels
to the extent produced by oncogenic ras, implying that
another ras-inducible factor contributes to p53 activa-
tion. An obvious candidate for this activity is p14ARF,
which is essential for p53 activation and ras-induced ar-
rest in MEFs (Palmero et al. 1998). However, we have
been unable to detect p14ARF induction by oncogenic ras
in human diploid fibroblasts, raising the possibility that
a different factor cooperates with PML to stabilize p53.
PML has a potent ability to force p53 to the PODs (Fig.
7); this may result from a direct protein–protein interac-
tion (G. del Sal, pers. comm.). Furthermore, like onco-
genic ras, PML is able to promote the phosphorylation of
p53 on serine 15. This effect is likely indirect, because
PML is not known to possess kinase activity. SP-15 p53
displays an increased ability to associate with CBP (Lam-
bert et al. 1998), a known POD component and p53 tran-
scriptional coactivator (Lill et al. 1997; LaMorte et al.
1998). In principle, serine 15 phosphorylation might ac-
tively recruit p53 to the PODs or, alternatively, might
occur as a consequence of p53 relocalization. In any case,
the ability of E1A to suppress serine-15 phosphorylation
correlates with its ability to circumvent ras-induced ar-
rest. Interestingly, ectopic p53 expression at levels simi-
lar to that produced by oncogenic ras did not induce
PS-15 p53 or senescence (Figs. 3B,6B), raising the pro-
vocative possibility that PML converts p53 into a senes-
cence inducer.
Implications for multistep carcinogenesis
In summary, our results indicate that PML participates
in the control of cellular senescence and further define
the mechanism of ras-induced arrest. In human cells,
this program involves multiple tumor-suppressor pro-
teins that form a tumor-suppressor network of activities
working on and reinforcing each other (Fig. 8). As a con-
sequence, growth suppression is tightly controlled and
difficult to overcome. Although loss-of-function muta-
tions in PML have not been described, PML dysfunction
produced by the PML-RAR fusion protein promotes
neoplasia, and PML inactivation produces tumor-prone
mice (reviewed by Melnick and Licht 1999). Interest-
ingly, PML-null mice are highly prone to papilloma for-
mation following skin treatment with the carcinogen di-
methylbenzanthracene and the tumor promoter 12-O-
tetradecanoylphorbol-13-acetate (Wang et al. 1998b).
Because this experimental paradigm inevitably produces
ras mutations, these results imply that oncogenic ras
Figure 8. A tumor suppressor network is activated by onco-
genic ras and inhibited by E1A in human diploid fibroblasts.
Expression of oncogenic ras in human diploid fibroblasts in-
duces first uncontrolled proliferation and then a permanent cell-
cycle arrest with characteristics of cellular senescence. The pro-
cess involves the mitogen-associated protein (MAP) kinase
pathway (Lin et al. 1998) and the tumor suppressors p53, p16, Rb
(Serrano et al. 1997) and PML (this paper). PML modulates both
the Rb and p53 pathways but may have additional activities.
Lesions that alter individual tumor suppressors in isolation do
not override ras-induced arrest (Serrano et al. 1997; Morales et
al. 1999). However, E1A disables multiple tumor-suppressor
pathways and, hence, overrides ras-induced arrest (see bars).
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and PML inactivation cooperate during tumor develop-
ment. Together, these data establish a new activity of
PML that may be important in tumor suppression.
Materials and methods
Cells and retroviruses
Normal human diploid fibroblasts IMR90 (PDL 22–25) ex-
pressed the murine ecotropic receptor to allow infection with
murine retroviruses (Serrano et al. 1997). They were cultured in
Dulbecco’s modified Eagle medium (DMEM, GIBCO) supple-
mented with 10% fetal bovine serum (FBS, Hyclone, Utah) and
1% penicillin G/streptomycin sulfate (Sigma). Retroviral-medi-
ated gene transfer was performed using Phoenix packaging cells
as previously described (Serrano et al. 1997). Oncogenic ras (H-
RasV12) was expressed using pBabe-ras or pWZL-ras (Serrano et
al. 1997). PML (Mu et al. 1994), PMLnls- and PMLprb- (provided
by Dr. K.S. Chang) were expressed using pLPC or pWZL Hygro
(McCurrach et al. 1997). E1A was expressed using pLPC-12S
(Samuelson and Lowe 1997). Human p53 was expressed using
either pLPC-hp53 (McCurrach et al. 1997) or p53GFP (provided
by G. Hannon). Infected cell populations were selected in either
puromycin (2.5 µg/ml, 3 days) or hygromycin (100 µg/ml, 5
days).
Gene expression
Cells used for differential gene expression studies were prepared
as follows: IMR90 cells were infected with retroviruses express-
ing oncogenic ras (Babe-ras) or an empty vector control (Babe-
puro). Infected cell populations were selected in puromycin for
2 days. Three days postselection, the cells were subcultured 1:3
and cultured for another 7 days. Under these conditions, control
populations become highly confluent and arrest by contact in-
hibition, whereas ras-expressing cells arrest at subconfluent
density. In these test populations, cell-cycle arrest was con-
firmed by 3H-thymidine incorporation (see below), and senes-
cence was confirmed by quantifying the percentage of cells that
were positive for SA--gal (Dimri et al. 1995). mRNA was ex-
tracted from cells 10 days postselection (PolyATtract system
1000, Promega), and hybridization probes were prepared from
2.5 µg of mRNA by reverse transcription in the presence of
33P-dCTP. Differential gene expression was assessed using Ge-
nome Discovery Arrays (GDA 1.2, Genome Systems) contain-
ing 18,376 cDNAs according to the manufacturers recom-
mendations. Data were collected in a Molecular Dynamics
PhosphorImager and the files were sent electronically to the
manufacturer for analysis.
The overall quality of the data was estimated from the ability
of our results to identify known changes induced during cellular
senescence. The genes for PAI-1 (Goldstein et al. 1994; Mu and
Higgins 1995), interleukin-1 (Kumar et al. 1993), stromelysin
(Millis et al. 1992), p21 (Noda et al. 1994), and SOD (Chang et al.
2000) were all found up-regulated in ras-expressing cells. In ad-
dition, we detected similar changes in expression of nonover-
lapping ESTs corresponding to the same gene. To validate spe-
cific changes, Northern blots were conducted using total RNA
purified using RNAzol, (Biotecx Labs, Houston, Texas). Twenty
µg of total RNA was fractionated on 1.2% formaldehyde–aga-
rose gels and transferred to Hybond-N nylon membranes (Am-
ersham) in 20× SSC (1× SSC is 0.15 M NaCl, 0.015 M sodium
citrate at pH 7.0, and 0.1% SDS). Hybridization was performed
at 65° C with 32P-labeled probes in 7% SDS, 0.25 M phosphate
buffer (pH 7.4), 1% BSA and 1 mM EDTA. The membranes were
washed twice at 65° C in 2× SSC for 10 min and once in 0.2×
SSC for 30 min. Probes for PML, stromelysin, and IL-1 con-
sisted of overlapping 60 mer oligonucleotides and were labeled
using Klenow polymerase as described (Wong and Goeddel
1994). The sequences of these probes are available upon request.
The probes for PAI-1 (Serrano et al. 1997) and 18S rRNA were
labeled by random priming (T7 QuickPrime, Pharmacia Bio-
tech, Inc.).
Cell proliferation
Cell proliferation was assessed using several assays. For growth
curves, cells were plated at 2.5 × 104 per well in 12-well plates,
and relative cell numbers were estimated at various times using
a crystal violet incorporation assay as previously described (Ser-
rano et al. 1997). To assess 3H-thymidine incorporation, cells
were plated as above at day-3 postselection. After 12 hrs, the
cells were pulsed for 24 hrs with 5 µCi/ml [methyl-3H]-thymi-
dine (Amersham, 2Ci/mM), washed with PBS, and detached us-
ing trypsin. Incorporated 3H-thymidine was precipitated in the
presence of ice-cold 10% TCA for 5 min, collected on glass-fiber
filters (Filtermat, Wallac), and quantified by scintillation count-
ing. To generate cell-cycle profiles of various populations, sub-
confluent cultures (day-4 postselection) were incubated in the
presence of 10 µM BrdU (Amersham) for 4 hr, fixed, and prepared
for flow cytometry as previously described (Lin et al. 1998). To
visualize BrdU incorporation in situ, subconfluent cultures
were incubated for 2 hrs in the presence of 10 µM BrdU, fixed,
and nuclei incorporating BrdU were visualized by immuno-
staining using a commercially available kit (Cell proliferation
kit, Amersham Pharmacia Biotech).
Protein expression
Immunoblots were performed from whole cell lysates as previ-
ously described (de Stanchina et al. 1998). 20 µg of protein/
sample were resolved on SDS-PAGE gels and transferred to Im-
mobilon-P membranes (Millipore). Antibodies against p53
(CM1, 1:2500, Novocastra), PS-15 p53 (16G8, 1:1000, New En-
gland Biolabs), p21 (C19, 1:500, Santa Cruz), Ras (OP23, 1:500,
Calbiochem) p16 (DCS-50, Novocastra, 1:200), Rb (G3-245;
Pharmigen, 1:1000), cyclin A (BF683, Santa Cruz, 1:500), Mdm2
(2A10, provided by A. Levine, 1:250), and -tubulin (B-5-1-2,
Sigma, 1:2000) were used as probes and detected using enhanced
chemiluminescence (ECL, Amersham, or SuperSignal West
Femtomaximum, Pierce). To detect PML, we used a monoclonal
antibody (PGM-3, 1:500, Santa Cruz) raised against amino acids
37–51 or a rabbit polyclonal antibody (provided by K.S. Chang,
1:500) directed against amino acids 352–366.
Fluorescence microscopy
Cells were plated on coverslips for at least 24 hr and fixed using
4% paraformaldehyde in PBS for 15 min at room temperature.
After washing with PBS, cells were permeablized for 5 min on
ice with 0.2% Triton X-100 in PBS with 3% BSA (PBS/BSA).
Then the cells were washed with PBS/BSA and incubated for 1
hr with different primary antibodies diluted in PBS/BSA, anti-
p53 (CM1, 1:50, Novocastra), anti-Rb (aRB1C1, 1:50, provided
by G. Klein), anti-PML (PGM-3, 1:200, Santa Cruz), anti-PML
rabbit polyclonal (provided by K.S. Chang, 1:1000) and anti-
Sp100 (AB1380, Chemicon Int., 1:500). After washing in PBS/
BSA, cells were stained with FITC or Texas Red-conjugated sec-
ondary antibodies, (1:200) for 45 min at room temperature in a
humidified chamber. Finally, cells were washed in PBS, stained
with 4,6-diamidino-2-phenylindole (DAPI) at a concentration of
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0.1 µg/ml in PBS and mounted on microscope slides. For stan-
dard fluorescence detection, we used a Zeiss immunofluores-
cence microscope (Axioscop 50, Thornwood, NY). Confocal im-
ages were obtained using a Zeiss LSM 510 confocal laser scan-
ning microscope (Thornwood, NY) using simultaneous scans to
avoid shift between the two optical channels. Data were col-
lected with eightfold averaging at a resolution of 512 × 512 pix-
els using the LSM 510 software and exported for printing using
Adobe Photoshop.
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Note added in proof
Pearson et al. (Nature 406: 207–210) have recently shown that
PML is required for ras-induced arrest in murine fibroblasts.
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